WHAT ACTIVITIES DOES LAB282 SUPPORT?
LAB282 can help academics access a wide range of early stage drug discovery and development capabilities, including those available through LAB282 partner Evotec and described below.
You have identified a novel small molecule for cancer therapy with exciting in vivo and in vitro biological properties. Since the chemical matter was identified by phenotypic screening, the actual target(s) is/are not known.
In order to de-convolute the target space, we offer to apply proprietary state-of-the-art transcriptomic and/or proteomic technologies such as CTPTM (Cellular Target Profiling) to identify and validate target candidates.
You have identified a target candidate for a novel anti-inflammatory therapeutic small molecule, but conclusive evidence that the target is related to the proposed mechanism-of-action is missing.
We will apply our expertise in differential expression studies followed by bioinformatics-driven data mining and hypothesis building as well as our in vitro and in vivo gene knock-out and over-expression studies -including CRISPR-Cas9 gene editing technologies – to validate your target candidate.
SCREENING & HIT IDENTIFICATION
You have established a novel assay to test small molecules for their potential to treat Type 2 Diabetes.
We are able to perform screening for biochemical, functional and cellular responses using our proprietary high-throughput screening technology or other commercial platforms. This can be through providing access to Evotec’s 400,000 compound screening library together with an exclusive access to the Sanofi library of 700,000 molecules.
Evotec’s technology platform includes nuclear magnetic resonance spectrometry, surface plasmon resonance spectrometry, high-content screening, high-throughput mass-spectrometry based screening and a comprehensive structure-based drug design platform applicable all major target classes.
TESTING NOVEL THERAPEUTICS IN IN VITRO MODELS
You have developed a therapeutic antibody against a first-in-class target to treat Alzheimer’s disease. Your antibody has excellent on-target activity but its cellular effects in a physiological context are difficult to study.
We offer to characterize the potency, selectivity and the functional effects of your antibody in a complex cellular (neuronal) environment and to perform the necessary translational studies by testing the proposed mechanism of your antibody using disease-relevant primary cells from rodents, primates or humans.
TESTING NOVEL THERAPEUTICS IN IN VIVO MODELS
You have generated a candidate for a novel broad-spectrum antibiotic with break-through therapeutic potential.
We will work with you to identify the most appropriate in vivo model(s) to interrogate pharmacodynamics effects and the therapeutic efficacy of your antibiotic candidate. All experimental procedures involving animals are carried out to the highest standards of animal welfare in state-of-the-art facilities and approved according to European Union as well as UK and other national regulations.
DRUG METABOLISM AND PHARMACOKINETICS (DMPK)
You have identified a novel lead candidate for the treatment of cardiovascular diseases but you are uncertain whether there will be a therapeutic window.
Successful small molecule drug discovery requires a deep understanding of the biological context coupled with knowledge and experience of the property space required to deliver safe, efficacious drugs. DMPK continues to be a key player in this success since the major sources of attrition – clinical efficacy and safety – are clearly linked to exposure in key tissues either on- or off-target. Thus, we offer a comprehensive and flexible range of in vitro and in vivo DMPK studies designed to cover the relevant activities in the lead-to-candidate phase.
Using your collaborator’s library, you have identified four small molecule hit series for a novel targeted tumor therapy. Prioritisation of the four series will depend inter alia on the determination of the structure-activity-relationship of the different series.
We will be able to support your project by designing, synthesizing and scaling up the analogues required to test your compounds in the most relevant biological systems and to develop them further into safe and efficacious treatments.
PROTEOMICS AND METABOLOMICS
You have designed a novel cell therapy to treat haematological malignancies but you are unsure which patient stratification strategy you should apply for your planned a first-in-man study.
We offer unique proteomics and metabolomics capabilities to address key issues in drug and biomarker discovery. We continuously advance our capabilities in mass spectrometry-based proteomics and metabolomics to ensure unrivalled comprehensiveness and data quality when analysing cells, animal models and patient samples. Applying our capabilities to your project, we will help you to identify the patient subset which may respond best to your novel therapy.